Literature DB >> 11356113

Enantioselective syntheses of dopaminergic (R)- and (S)-benzyltetrahydroisoquinolines.

N Cabedo1, I Andreu, M C Ramírez De Arellano, A Chagraoui, A Serrano, A Bermejo, P Protais, D Cortes.   

Abstract

Optically pure (1S,R)- and (1R,S)-benzyltetrahydroisoquinolines (BTHIQs), 12a,b as the major diastereomers, were prepared by stereoselective reduction of the isoquinolinium salt possessing (R)- and (S)-phenylglycinol as the chiral auxiliary, respectively. The absolute configurations of (1S,R)-13a hydrochloride (O-debenzoylated derivative from 12a) and (1R,S)-12b diastereomers were unambiguously determined by single-crystal X-ray analysis. Reductive removal of the chiral auxiliary group, subsequent N-propylation, and cleavage of the methylenedioxy group furnished the optically active catecholamines (1S)-16a and (1R)-16b in good overall yield. We have separately prepared for the first time pairs of dopaminergic 1-BTHIQs enantiomers through a classical methodology in asymmetric synthesis. The (1S)-enantiomers (14a-16a) bind to D1 and D2 dopamine receptors with affinities 5-15 times higher than those of the corresponding (1R)-enantiomers (14b-16b). Moreover, (1S)-14a inhibits [3H]dopamine uptake with high affinity. It appears that synthesis and testing of (S)-enantiomers of BTHIQ are very important for the search for new active drugs at dopamine receptors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11356113     DOI: 10.1021/jm001128u

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  Tetrahydroisoquinolines acting as dopaminergic ligands. A molecular modeling study using MD simulations and QM calculations.

Authors:  Sebastián Andujar; Fernando Suvire; Inmaculada Berenguer; Nuria Cabedo; Paloma Marín; Laura Moreno; María Dolores Ivorra; Diego Cortes; Ricardo D Enriz
Journal:  J Mol Model       Date:  2011-04-27       Impact factor: 1.810

2.  Hydroxybenzothiazoles as new nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1).

Authors:  Alessandro Spadaro; Matthias Negri; Sandrine Marchais-Oberwinkler; Emmanuel Bey; Martin Frotscher
Journal:  PLoS One       Date:  2012-01-05       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.